Global Perspectives on Multiple Myeloma in 2021 and Beyond

Clinical experts from the US discuss global perspectives on current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches.

September 17 and 18, 2021

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ, US

Faculty Members

Leif Bergsagel, MD 
Mayo Clinic, Scottsdale, AZ, USA

Irene Ghobrial, MD
Harvard Medical School, Dana-Farber Cancer Center, Boston, MA, USA

Craig Hofmeister, MD, MPH
Emory University School of Medicine, Atlanta, GA, USA

Nina Shah, MD
UCSF Health, San Francisco, CA, USA

Keith Stewart, MBChB
University Health Network, Toronto, Canada

Tom Martin, MD 
University of California San Francisco Medical Center, USA

Sagar Lonial, MD
Winship Cancer Institute of Emory University, Atlanta, GA, USA

Peter Voorhees, MD
Levine Cancer Institute, Charlotte, NC

Faith Davies, , MD
NYU Langone , New York, NY

Sample Report

Start discovering the insights

View Report


  • Pursuing the Cure for Myeloma
  • IMiDs – With Us Since 1999
  • The Evolving Role of Proteasome Inhibitors (PIs)
  • Monoclonal Anti-CD38
  • CAR T Therapies for the Treatment of MM
  • Bispecifics for the Treatment of MM
  • Other Agents on the Horizon in MM and Moving the Needle Forward

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.